{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:17:37Z","timestamp":1775783857643,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Restless Legs Syndrome (RLS) is a neurological sensorimotor disorder negatively impacting sufferers\u2019 quality of sleep and health-related quality of life. The pathophysiology of RLS is poorly understood and research focusing on the link between RLS and inflammation has been limited. Our study aimed to investigate whether chronic inflammation markers C-reactive protein (CRP) and soluble urokinase-type plasminogen activator receptor (suPAR), as well plasma levels of five different cytokine-specific autoantibodies (c-aAb), i.e. modulators of inflammation, associate with RLS in otherwise healthy individuals. CRP, suPAR and c-aAb were measured in plasma samples of participants from the Danish Blood Donor Study in 2010. Returning donors between 2015 and 2018 completed the validated Cambridge-Hopkins RLS-questionnaire for RLS assessment, resulting in datasets with RLS assessment and values for CRP (N\u2009=\u20093564), suPAR (N\u2009=\u20092546) and c-aAb (N\u2009=\u20091478). We performed logistic regression models using the CRP, suPAR or c-aAb as the independent variable and RLS status as the dependent variable, adjusted for appropriate covariates. Our study indicates that a high concentration of CRP is associated with RLS, while an increased probability of experiencing frequent RLS symptoms in those with an elevated plasma suPAR level appears to be mediated through lifestyle factors. We additionally report that a high titer of autoantibodies specific against the cytokine interferon-alpha was associated with RLS. Our results support the existence of links between systemic inflammation and RLS, though further RLS studies on CRP, suPAR and c-aAb in larger cohorts are warranted to confirm our findings and further reveal the hitherto underexplored links between RLS and inflammation.<\/jats:p>","DOI":"10.1038\/s41598-022-05658-1","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:18:28Z","timestamp":1643627908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-2633","authenticated-orcid":false,"given":"Joseph","family":"Dowsett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Didriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob Hjorth","family":"von Stemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margit H\u00f8rup","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Wegner","family":"Th\u00f8rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Erikstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Birger","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Bagge","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Eugen-Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Banasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"5658_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.sleep.2017.04.014","volume":"36","author":"M Didriksen","year":"2017","unstructured":"Didriksen, M. et al. Prevalence of restless legs syndrome and associated factors in an otherwise healthy population: Results from the Danish blood donor study. Sleep Med. 36, 55\u201361. https:\/\/doi.org\/10.1016\/j.sleep.2017.04.014 (2017).","journal-title":"Sleep Med."},{"key":"5658_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/vox.12123","volume":"107","author":"B Pedrazzini","year":"2014","unstructured":"Pedrazzini, B. et al. Prevalence of restless legs syndrome in female blood donors 1 week after blood donation. Vox Sang. 107, 44\u201349. https:\/\/doi.org\/10.1111\/vox.12123 (2014).","journal-title":"Vox Sang."},{"key":"5658_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s11325-011-0606-x","volume":"16","author":"P Yeh","year":"2012","unstructured":"Yeh, P., Walters, A. S. & Tsuang, J. W. Restless legs syndrome: A comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath. = Schlaf Atmung 16, 987\u20131007. https:\/\/doi.org\/10.1007\/s11325-011-0606-x (2012).","journal-title":"Sleep Breath. = Schlaf Atmung"},{"key":"5658_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.sleep.2018.02.007","volume":"45","author":"M Didriksen","year":"2018","unstructured":"Didriksen, M. et al. Restless legs syndrome is associated with major comorbidities in a population of Danish blood donors. Sleep Med. 45, 124\u2013131. https:\/\/doi.org\/10.1016\/j.sleep.2018.02.007 (2018).","journal-title":"Sleep Med."},{"key":"5658_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen, R. P. et al. Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: Updated International restless legs syndrome study group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance. Sleep Med. 15, 860\u2013873. https:\/\/doi.org\/10.1016\/j.sleep.2014.03.025 (2014).","journal-title":"Sleep Med."},{"key":"5658_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5664\/jcsm.5482","volume":"12","author":"S Batool-Anwar","year":"2016","unstructured":"Batool-Anwar, S. et al. Lifestyle factors and risk of restless legs syndrome: Prospective cohort study. J. Clin. Sleep Med. 12, 187\u2013194. https:\/\/doi.org\/10.5664\/jcsm.5482 (2016).","journal-title":"J. Clin. Sleep Med."},{"key":"5658_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fnagi.2017.00171","volume":"9","author":"S Guo","year":"2017","unstructured":"Guo, S. et al. Restless legs syndrome: From pathophysiology to clinical diagnosis and management. Front. Aging Neurosci. 9, 171\u2013171. https:\/\/doi.org\/10.3389\/fnagi.2017.00171 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"5658_CR8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.chest.2020.03.035","volume":"158","author":"S Romero-Peralta","year":"2020","unstructured":"Romero-Peralta, S., Cano-Pumarega, I. & Garc\u00eda-Borreguero, D. Emerging concepts of the pathophysiology and adverse outcomes of restless legs syndrome. Chest 158, 1218\u20131229. https:\/\/doi.org\/10.1016\/j.chest.2020.03.035 (2020).","journal-title":"Chest"},{"key":"5658_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.smrv.2011.09.003","volume":"16","author":"LB Weinstock","year":"2012","unstructured":"Weinstock, L. B., Walters, A. S. & Paueksakon, P. Restless legs syndrome\u2013theoretical roles of inflammatory and immune mechanisms. Sleep Med. Rev. 16, 341\u2013354. https:\/\/doi.org\/10.1016\/j.smrv.2011.09.003 (2012).","journal-title":"Sleep Med. Rev."},{"key":"5658_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.sleep.2019.02.022","volume":"58","author":"HO Yazar","year":"2019","unstructured":"Yazar, H. O., Yazar, T., \u00d6zdemir, S. & Arici, Y. K. Serum C-reactive protein\/albumin ratio and restless legs syndrome. Sleep Med. 58, 61\u201365. https:\/\/doi.org\/10.1016\/j.sleep.2019.02.022 (2019).","journal-title":"Sleep Med."},{"key":"5658_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.sleep.2015.03.025","volume":"16","author":"T Higuchi","year":"2015","unstructured":"Higuchi, T. et al. Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis. Sleep Med. 16, 941\u2013948. https:\/\/doi.org\/10.1016\/j.sleep.2015.03.025 (2015).","journal-title":"Sleep Med."},{"key":"5658_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-020-02218-7","author":"FI Uslu","year":"2020","unstructured":"Uslu, F. I., Demir, E., Guler, E. M. & Kocyigit, A. Circulating levels of cytokines are increased in restless legs syndrome. Sleep Breath. https:\/\/doi.org\/10.1007\/s11325-020-02218-7 (2020).","journal-title":"Sleep Breath."},{"key":"5658_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.11622\/smedj.2016154","volume":"57","author":"C Var\u0131m","year":"2016","unstructured":"Var\u0131m, C. et al. Association between the neutrophil-to-lymphocyte ratio, a new marker of systemic inflammation, and restless legs syndrome. Singap. Med. J. 57, 514\u2013516. https:\/\/doi.org\/10.11622\/smedj.2016154 (2016).","journal-title":"Singap. Med. J."},{"key":"5658_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.sleep.2010.08.006","volume":"11","author":"B Benediktsdottir","year":"2010","unstructured":"Benediktsdottir, B. et al. Prevalence of restless legs syndrome among adults in Iceland and Sweden: Lung function, comorbidity, ferritin, biomarkers and quality of life. Sleep Med. 11, 1043\u20131048. https:\/\/doi.org\/10.1016\/j.sleep.2010.08.006 (2010).","journal-title":"Sleep Med."},{"key":"5658_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4274\/tnd.98474","volume":"24","author":"AZA Tak","year":"2018","unstructured":"Tak, A. Z. A. & Sengul, Y. Evaluation of inflammation with neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in restless legs syndrome. Turk. J. Neurol. 24, 259\u2013263. https:\/\/doi.org\/10.4274\/tnd.98474 (2018).","journal-title":"Turk. J. Neurol."},{"key":"5658_CR16","doi-asserted-by":"publisher","first-page":"e0259681","DOI":"10.1371\/journal.pone.0259681","volume":"16","author":"J Dowsett","year":"2021","unstructured":"Dowsett, J. et al. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome. PLoS ONE 16, e0259681. https:\/\/doi.org\/10.1371\/journal.pone.0259681 (2021).","journal-title":"PLoS ONE"},{"key":"5658_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.bbi.2012.06.003","volume":"26","author":"LM Trotti","year":"2012","unstructured":"Trotti, L. M. et al. Elevated C-reactive protein is associated with severe periodic leg movements of sleep in patients with restless legs syndrome. Brain Behav. Immun. 26, 1239\u20131243. https:\/\/doi.org\/10.1016\/j.bbi.2012.06.003 (2012).","journal-title":"Brain Behav. Immun."},{"key":"5658_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","volume":"268","author":"J Eugen-Olsen","year":"2010","unstructured":"Eugen-Olsen, J. et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J. Intern. Med. 268, 296\u2013308. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02252.x (2010).","journal-title":"J. Intern. Med."},{"key":"5658_CR19","doi-asserted-by":"publisher","first-page":"e110555","DOI":"10.1371\/journal.pone.0110555","volume":"9","author":"E Haastrup","year":"2014","unstructured":"Haastrup, E. et al. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS ONE 9, e110555. https:\/\/doi.org\/10.1371\/journal.pone.0110555 (2014).","journal-title":"PLoS ONE"},{"key":"5658_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1017\/S0007114518003720","volume":"121","author":"PBS Tornkvist","year":"2019","unstructured":"Tornkvist, P. B. S. et al. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality. Br. J. Nutr. 121, 699\u2013708. https:\/\/doi.org\/10.1017\/S0007114518003720 (2019).","journal-title":"Br. J. Nutr."},{"key":"5658_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41577-019-0131-x","volume":"19","author":"G Altan-Bonnet","year":"2019","unstructured":"Altan-Bonnet, G. & Mukherjee, R. Cytokine-mediated communication: A quantitative appraisal of immune complexity. Nat. Rev. Immunol. 19, 205\u2013217. https:\/\/doi.org\/10.1038\/s41577-019-0131-x (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"5658_CR22","doi-asserted-by":"publisher","first-page":"e0179981","DOI":"10.1371\/journal.pone.0179981","volume":"12","author":"JH von Stemann","year":"2017","unstructured":"von Stemann, J. H. et al. Prevalence and correlation of cytokine-specific autoantibodies with epidemiological factors and C-reactive protein in 8972 healthy individuals: Results from the Danish blood donor study. PLoS ONE 12, e0179981. https:\/\/doi.org\/10.1371\/journal.pone.0179981 (2017).","journal-title":"PLoS ONE"},{"key":"5658_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.autrev.2015.01.015","volume":"14","author":"T Vincent","year":"2015","unstructured":"Vincent, T., Plawecki, M., Goulabchand, R., Guilpain, P. & Eliaou, J. F. Emerging clinical phenotypes associated with anti-cytokine autoantibodies. Autoimmun. Rev. 14, 528\u2013535. https:\/\/doi.org\/10.1016\/j.autrev.2015.01.015 (2015).","journal-title":"Autoimmun. Rev."},{"key":"5658_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmpb.2016.07.023","volume":"135","author":"KS Burgdorf","year":"2016","unstructured":"Burgdorf, K. S. et al. Digital questionnaire platform in the Danish blood donor study. Comput. Methods Progr. Biomed. 135, 101\u2013104. https:\/\/doi.org\/10.1016\/j.cmpb.2016.07.023 (2016).","journal-title":"Comput. Methods Progr. Biomed."},{"key":"5658_CR25","doi-asserted-by":"publisher","first-page":"e88196","DOI":"10.1371\/journal.pone.0088196","volume":"9","author":"CJ S\u00f8rensen","year":"2014","unstructured":"S\u00f8rensen, C. J. et al. Combined oral contraception and obesity are strong predictors of low-grade inflammation in healthy individuals: Results from the Danish blood donor study (DBDS). PLoS ONE 9, e88196. https:\/\/doi.org\/10.1371\/journal.pone.0088196 (2014).","journal-title":"PLoS ONE"},{"key":"5658_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1373\/49.4.666","volume":"49","author":"N Rifai","year":"2003","unstructured":"Rifai, N. & Ridker, P. M. Population distributions of C-reactive protein in apparently healthy men and women in the United States: Implication for clinical interpretation. Clin. Chem. 49, 666\u2013669. https:\/\/doi.org\/10.1373\/49.4.666 (2003).","journal-title":"Clin. Chem."},{"key":"5658_CR27","doi-asserted-by":"publisher","first-page":"e0164220","DOI":"10.1371\/journal.pone.0164220","volume":"11","author":"KA Kaspersen","year":"2016","unstructured":"Kaspersen, K. A. et al. Low-grade inflammation is associated with susceptibility to infection in healthy men: Results from the Danish blood donor study (DBDS). PLoS ONE 11, e0164220. https:\/\/doi.org\/10.1371\/journal.pone.0164220 (2016).","journal-title":"PLoS ONE"},{"key":"5658_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.clinbiochem.2019.05.010","volume":"69","author":"J Chew-Harris","year":"2019","unstructured":"Chew-Harris, J., Appleby, S., Richards, A. M., Troughton, R. W. & Pemberton, C. J. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. Clin. Biochem. 69, 36\u201344. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.05.010 (2019).","journal-title":"Clin. Biochem."},{"key":"5658_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jim.2015.06.010","volume":"425","author":"DKR Guldager","year":"2015","unstructured":"Guldager, D. K. R. et al. A rapid, accurate and robust particle-based assay for the simultaneous screening of plasma samples for the presence of five different anti-cytokine autoantibodies. J. Immunol. Methods 425, 62\u201368. https:\/\/doi.org\/10.1016\/j.jim.2015.06.010 (2015).","journal-title":"J. Immunol. Methods"},{"key":"5658_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mds.23430","volume":"26","author":"RP Allen","year":"2011","unstructured":"Allen, R. P., Bharmal, M. & Calloway, M. Prevalence and disease burden of primary restless legs syndrome: Results of a general population survey in the United States. Mov. Disord. 26, 114\u2013120. https:\/\/doi.org\/10.1002\/mds.23430 (2011).","journal-title":"Mov. Disord."},{"key":"5658_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/eci.12593","volume":"46","author":"J Eugen-Olsen","year":"2016","unstructured":"Eugen-Olsen, J., Ladelund, S. & Sorensen, L. T. Plasma suPAR is lowered by smoking cessation: A randomized controlled study. Eur. J. Clin. Invest. 46, 305\u2013311. https:\/\/doi.org\/10.1111\/eci.12593 (2016).","journal-title":"Eur. J. Clin. Invest."},{"key":"5658_CR32","doi-asserted-by":"publisher","first-page":"BMI.SI19876","DOI":"10.4137\/BMI.S19876","volume":"9","author":"TH Haupt","year":"2014","unstructured":"Haupt, T. H. et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark. Insights 9, BMI.SI19876. https:\/\/doi.org\/10.4137\/BMI.S19876 (2014).","journal-title":"Biomark. Insights"},{"key":"5658_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-018-0141-8","author":"TH Haupt","year":"2019","unstructured":"Haupt, T. H. et al. Healthy lifestyles reduce suPAR and mortality in aDanish general population study. Immun. Ageing https:\/\/doi.org\/10.1186\/s12979-018-0141-8 (2019).","journal-title":"Immun. Ageing"},{"key":"5658_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ijcard.2012.03.040","volume":"167","author":"S Lyngbaek","year":"2013","unstructured":"Lyngbaek, S. et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int. J. Cardiol. 167, 781\u2013785. https:\/\/doi.org\/10.1016\/j.ijcard.2012.03.040 (2013).","journal-title":"Int. J. Cardiol."},{"key":"5658_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jmv.21114","volume":"80","author":"O Andersen","year":"2008","unstructured":"Andersen, O., Eugen-Olsen, J., Kofoed, K., Iversen, J. & Haugaard, S. B. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J. Med. Virol. 80, 209\u2013216. https:\/\/doi.org\/10.1002\/jmv.21114 (2008).","journal-title":"J. Med. Virol."},{"key":"5658_CR36","first-page":"717","volume":"79","author":"CF Sier","year":"1999","unstructured":"Sier, C. F. et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab. Investig. J. Tech. Methods Pathol. 79, 717\u2013722 (1999).","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"5658_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cca.2014.10.004","volume":"439","author":"T Thurison","year":"2015","unstructured":"Thurison, T., Christensen, I. J., Lund, I. K., Nielsen, H. J. & H\u00f8yer-Hansen, G. Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: Biological variation, reference intervals and clinical useful cut-points. Clin. Chim. Acta 439, 84\u201390. https:\/\/doi.org\/10.1016\/j.cca.2014.10.004 (2015).","journal-title":"Clin. Chim. Acta"},{"key":"5658_CR38","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1002\/art.30399","volume":"63","author":"AM Morimoto","year":"2011","unstructured":"Morimoto, A. M. et al. Association of endogenous anti\u2013interferon-\u03b1 autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthr. Rheum. 63, 2407\u20132415. https:\/\/doi.org\/10.1002\/art.30399 (2011).","journal-title":"Arthr. Rheum."},{"key":"5658_CR39","doi-asserted-by":"publisher","first-page":"e32001","DOI":"10.1371\/journal.pone.0032001","volume":"7","author":"KH Ching","year":"2012","unstructured":"Ching, K. H. et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE 7, e32001. https:\/\/doi.org\/10.1371\/journal.pone.0032001 (2012).","journal-title":"PLoS ONE"},{"key":"5658_CR40","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3892\/etm.2021.10234","volume":"22","author":"C Falup-Pecurariu","year":"2021","unstructured":"Falup-Pecurariu, C. et al. Restless legs syndrome in systemic lupus erythematosus: A case-control study. Exp. Ther. Med. 22, 802. https:\/\/doi.org\/10.3892\/etm.2021.10234 (2021).","journal-title":"Exp. Ther. Med."},{"key":"5658_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1756-185X.12793","volume":"20","author":"A Kucuk","year":"2017","unstructured":"Kucuk, A. et al. Relationship between prevalence and severity of restless legs syndrome and anemia in patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 20, 469\u2013473. https:\/\/doi.org\/10.1111\/1756-185X.12793 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"5658_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3899\/jrheum.101039","volume":"38","author":"N Hassan","year":"2011","unstructured":"Hassan, N. et al. Systemic lupus and risk of restless legs syndrome. J. Rheumatol. 38, 874\u2013876. https:\/\/doi.org\/10.3899\/jrheum.101039 (2011).","journal-title":"J. Rheumatol."},{"key":"5658_CR43","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mds.20049","volume":"19","author":"JS LaRochelle","year":"2004","unstructured":"LaRochelle, J. S. & Karp, B. I. Restless legs syndrome due to interferon-\u03b1. Mov. Disord. 19, 730\u2013731. https:\/\/doi.org\/10.1002\/mds.20049 (2004).","journal-title":"Mov. Disord."},{"key":"5658_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0168-8278(94)80018-9","volume":"20","author":"P Bonetti","year":"1994","unstructured":"Bonetti, P. et al. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2<em>\u03b1<\/em>. J. Hepatol. 20, 416\u2013420. https:\/\/doi.org\/10.1016\/S0168-8278(94)80018-9 (1994).","journal-title":"J. Hepatol."},{"key":"5658_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","volume":"37","author":"BA Baldo","year":"2014","unstructured":"Baldo, B. A. Side effects of cytokines approved for therapy. Drug Saf. 37, 921\u2013943. https:\/\/doi.org\/10.1007\/s40264-014-0226-z (2014).","journal-title":"Drug Saf."},{"key":"5658_CR46","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/01.wnl.0000090041.02085.22","volume":"61","author":"EK Tan","year":"2003","unstructured":"Tan, E. K., Chan, L. L. & Lo, Y. L. \u201cMyorhythmia\u201d slow facial tremor from chronic interferon alpha-2a usage. Neurology 61, 1302\u20131303. https:\/\/doi.org\/10.1212\/01.wnl.0000090041.02085.22 (2003).","journal-title":"Neurology"},{"key":"5658_CR47","first-page":"204","volume":"14","author":"H Jabbari","year":"2011","unstructured":"Jabbari, H., Fakharzadeh, E., Merat, S., Zamini, H. & Sharifi, A. H. Bell\u2019s palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy. Arch. Iran. Med. 14, 204\u2013205 (2011).","journal-title":"Arch. Iran. Med."},{"key":"5658_CR48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.10118","volume":"25","author":"K Boonyapisit","year":"2002","unstructured":"Boonyapisit, K. & Katirji, B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: A case report and literature review. Muscle Nerve 25, 909\u2013913. https:\/\/doi.org\/10.1002\/mus.10118 (2002).","journal-title":"Muscle Nerve"},{"key":"5658_CR49","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/jci20945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113, 1271\u20131276. https:\/\/doi.org\/10.1172\/jci20945 (2004).","journal-title":"J. Clin. Investig."},{"key":"5658_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.sleep.2021.10.008","volume":"88","author":"J Dowsett","year":"2021","unstructured":"Dowsett, J. et al. No association between plasma hepcidin levels and restless legs syndrome: Results from the Danish blood donor study. Sleep Med. 88, 68\u201373. https:\/\/doi.org\/10.1016\/j.sleep.2021.10.008 (2021).","journal-title":"Sleep Med."},{"key":"5658_CR51","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/gerona\/glaa178","volume":"76","author":"LJH Rasmussen","year":"2021","unstructured":"Rasmussen, L. J. H. et al. Association between elevated suPAR, a new biomarker of inflammation, and accelerated aging. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 76, 318\u2013327. https:\/\/doi.org\/10.1093\/gerona\/glaa178 (2021).","journal-title":"J. Gerontol. Ser. A, Biol. Sci. Med. Sci."},{"key":"5658_CR52","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/eji.200425268","volume":"34","author":"P Galle","year":"2004","unstructured":"Galle, P., Svenson, M., Bendtzen, K. & Hansen, M. B. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur. J. Immunol. 34, 3267\u20133275. https:\/\/doi.org\/10.1002\/eji.200425268 (2004).","journal-title":"Eur. J. Immunol."},{"key":"5658_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.7916\/D83J3D2G","volume":"6","author":"BB Koo","year":"2016","unstructured":"Koo, B. B., Bagai, K. & Walters, A. S. Restless legs syndrome: Current concepts about disease pathophysiology. Tremor Other Hyperkinet Mov (N Y) 6, 401\u2013401. https:\/\/doi.org\/10.7916\/D83J3D2G (2016).","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"5658_CR54","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1474-4422(18)30311-9","volume":"17","author":"C Trenkwalder","year":"2018","unstructured":"Trenkwalder, C. et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 17, 994\u20131005. https:\/\/doi.org\/10.1016\/S1474-4422(18)30311-9 (2018).","journal-title":"Lancet Neurol."},{"key":"5658_CR55","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1468-1331.2011.03397.x","volume":"18","author":"SM Patton","year":"2011","unstructured":"Patton, S. M., Ponnuru, P., Snyder, A. M., Podskalny, G. D. & Connor, J. R. Hypoxia-inducible factor pathway activation in restless legs syndrome patients. Eur. J. Neurol. 18, 1329\u20131335. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03397.x (2011).","journal-title":"Eur. J. Neurol."},{"key":"5658_CR56","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.sleep.2011.11.012","volume":"13","author":"G Baskol","year":"2012","unstructured":"Baskol, G. et al. Assessment of nitric oxide, advanced oxidation protein products, malondialdehyde, and thiol levels in patients with restless legs syndrome. Sleep Med. 13, 414\u2013418. https:\/\/doi.org\/10.1016\/j.sleep.2011.11.012 (2012).","journal-title":"Sleep Med."},{"key":"5658_CR57","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/wnl.0000000000000454","volume":"82","author":"AV Salminen","year":"2014","unstructured":"Salminen, A. V., Rimpil\u00e4, V. & Polo, O. Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease). Neurology 82, 1856\u20131861. https:\/\/doi.org\/10.1212\/wnl.0000000000000454 (2014).","journal-title":"Neurology"},{"key":"5658_CR58","doi-asserted-by":"crossref","unstructured":"Imtiyaz, H. Z. & Simon, M. C. in Diverse Effects of Hypoxia on Tumor Progression (ed M. Celeste Simon) 105\u2013120 (Springer, Berlin Heidelberg, 2010).","DOI":"10.1007\/82_2010_74"},{"key":"5658_CR59","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.sleep.2020.09.002","volume":"75","author":"J-W Shin","year":"2020","unstructured":"Shin, J.-W. et al. Bioinformatic analysis of proteomic data for iron, inflammation, and hypoxic pathways in restless legs syndrome. Sleep Med. 75, 448\u2013455. https:\/\/doi.org\/10.1016\/j.sleep.2020.09.002 (2020).","journal-title":"Sleep Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05658-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:30:44Z","timestamp":1669329044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05658-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5658"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05658-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E.O. is named inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. J.E.O. is co-founder, shareholder and board member of ViroGates A\/S, Denmark, the company that developed the suPARnostic ELISA. ViroGates A\/S had no role in the study design, data collection, analysis or interpretation of study findings, and\/or in the decision to submit the manuscript for publication. The remaining authors have disclosed no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1672"}}